Mpox (monkeypox) vaccine Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix® Mpox vaccine safety surveillance conducted by AusVaxSafety was completed on 17 April 2023. Data on this page will no longer be updated. Safety data collected from more than 15,000 JYNNEOS mpox vaccine recipients identified no safety issues in either administration method, intradermal and subcutaneous.The Therapeutic Goods Administration (TGA) continues to monitor the safety of mpox vaccines in Australia. Mpox vaccine safety dataClick on the tiles below to view subcutaneous and intradermal mpox vaccine safety data. Intradermal JYNNEOS mpox (monkeypox) vaccine View the latest intradermal JYNNEOS mpox vaccine safety data here Subcutaneous JYNNEOS mpox (monkeypox) vaccine View the latest subcutaneous JYNNEOS mpox vaccine safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix® News & events All news & events 08 January 2025 | News New report re-affirms short-term safety of vaccines in Australia 08 November 2024 | News Enhanced National Immunisation Program vaccine safety data now available 23 October 2024 | News AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses 01 October 2024 | News AusVaxSafety marks a decade of progress in vaccine safety